U.S. markets closed
  • S&P 500

    3,298.46
    +51.87 (+1.60%)
     
  • Nasdaq

    10,913.56
    +241.26 (+2.26%)
     
  • Russell 2000

    1,474.91
    +23.09 (+1.59%)
     
  • Crude Oil

    40.04
    -0.27 (-0.67%)
     
  • Gold

    1,864.30
    -12.60 (-0.67%)
     
  • Silver

    22.99
    -0.21 (-0.91%)
     
  • EUR/USD

    1.1637
    -0.0038 (-0.3258%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • Vix

    26.38
    -2.13 (-7.47%)
     
  • GBP/USD

    1.2744
    -0.0008 (-0.0624%)
     
  • BTC-USD

    10,785.11
    +49.75 (+0.46%)
     
  • CMC Crypto 200

    230.19
    +12.36 (+5.67%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.82 (+0.51%)
     

Rite Aid Continues to Expand COVID-19 Testing

Twenty One Additional Self-Swab Testing Sites to Open Across Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania and Virginia

Rite Aid (NYSE: RAD) continues to expand COVID-19 testing sites with 21 additional drive-through locations opening Thursday, June 11, 2020, through its partnership with the U.S. Department of Health and Human Services (HHS).

Similar to Rite Aid’s existing testing sites, the new locations will utilize self-swab nasal tests overseen by Rite Aid pharmacists, and will operate Monday through Friday 10 a.m. - 8 p.m. and Saturday and Sunday 10 a.m. - 5 p.m.

Rite Aid’s COVID-19 nasal tests are available for all adults, regardless if they are experiencing virus symptoms, in accordance with the Centers for Disease Control and Prevention guidance. At all testing locations, patients are required to provide government issued identification, be at least 18 years old and need to pre-register online at www.riteaid.com in order to schedule a time slot for testing.

Rite Aid’s 92 locations will have the capacity to conduct nearly 47,000 tests weekly across all locations through online appointments. A complete list of Rite Aid's COVID-19 testing sites can be found at www.riteaid.com.

Rite Aid has partnered with Verily and will use its Baseline COVID-19 Program to provide screening, scheduling and return of results to participants for Rite Aid testing sites. Rite Aid has selected BioReference Laboratories to provide COVID-19 laboratory testing.

Clinical oversight for the COVID-19 testing program is provided by PWNHealth, a national clinician network that enables safe and easy access to diagnostic testing.

Rite Aid will continue to provide regular updates on the company's progress with COVID-19 testing.

About Rite Aid Corporation

Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to more than 1.6 million Americans daily. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,400 retail pharmacy locations across 18 states. Through EnvisionRxOptions, we provide pharmacy benefits and services to approximately 4 million members nationwide. For more information, www.riteaid.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005427/en/

Contacts

Chris Savarese
717-975-5718
christopher.savarese@riteaid.com